Takeda Pharmaceutical Co Ltd ADR
$ 15.91
0.25%
12 Jun - close price
- Market Cap 50,270,405,000 USD
- Current Price $ 15.91
- High / Low $ 16.02 / 15.85
- Stock P/E 43.00
- Book Value 15.34
- EPS 0.37
- Next Earning Report 2026-07-30
- Dividend Per Share $200.00
- Dividend Yield 4.16 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.03 %
- 52 Week High 18.90
- 52 Week Low 12.78
About
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Analyst Target Price
$20.69
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-29 | 2025-10-30 | 2025-07-30 | 2025-06-25 | 2025-01-30 | 2024-10-31 | 2024-07-31 | 2024-05-09 | 2024-02-01 | 2023-10-26 | 2023-07-27 | 2023-05-11 |
| Reported EPS | 0.2099 | -0.0253 | 151 | -0.2276 | 0.0478 | 29.07 | 0.1923 | -0.0065 | 33.79 | -15.5 | 28.76 | 0.074 |
| Estimated EPS | None | 0.151 | 0.2006 | -0.166 | 0.63 | 87.45 | 0.1228 | -0.0142 | 0.1085 | 0.1441 | 18.62 | 0.0505 |
| Surprise | 0 | -0.1763 | 150.7994 | -0.0616 | -0.5822 | -58.38 | 0.0695 | 0.0077 | 33.6815 | -15.6441 | 10.14 | 0.0235 |
| Surprise Percentage | None% | -116.755% | 75174.1775% | -37.1084% | -92.4127% | -66.7581% | 56.5961% | 54.2254% | 31042.8571% | -10856.4192% | 54.4576% | 46.5347% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.39 |
| Currency | JPY |
Previous Dividend Records
| Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 | None |
| Amount | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 | $0.4191 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2026-06-12 22:39:13
Takeda Pharmaceutical, the largest life-science employer in Massachusetts, is laying off 247 employees in Cambridge starting in July as part of a global restructuring plan to save $1.2 billion annually by 2028. These cuts are a response to the collapse of its blockbuster ADHD drug, VYVANSE, after losing its U.S. patent protection. The company is betting on three experimental drugs to replace lost revenue while offering internal roles to impacted employees.
2026-06-11 11:10:00
Takeda announced positive topline results from a head-to-head Phase 3 study showing its investigational oral drug, zasocitinib (TAK-279), significantly outperformed deucravacitinib in treating moderate-to-severe plaque psoriasis. Zasocitinib demonstrated statistical superiority in skin clearance, with over 35% of patients achieving complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of deucravacitinib. The drug was generally well-tolerated with no new safety signals, and Takeda plans to submit a New Drug Application for plaque psoriasis starting this fiscal year.
2026-06-11 07:09:15
May 2026 saw a significant spike in biopharma layoffs, with nearly 7,000 employees affected, a 47% increase year-over-year. The majority of these cuts came from Takeda and BioNTech, accounting for 6,360 positions, as they announced plans for streamlining operations and facility closures. Other companies like AbbVie, Amicus Therapeutics, Johnson & Johnson, Novartis, and Valneva also contributed to the workforce reductions, marking a challenging month for the industry.
2026-06-11 00:09:15
Takeda presented new oncology data at ASCO 2026, highlighting investigational and in-market drugs, with significant contributions from its partnership with Innovent Biologics. Teresa Bitetti and PK Morrow discussed how these presentations align with Takeda's broader strategy to expand into solid tumors and how ASCO helps pharma companies adapt their strategies to evolving standards of care and exciting trends in immune-oncology. The focus was on data from drugs like TAK-928 in non-small cell lung cancer and rusfertide in polycemia vera.
2026-06-10 11:40:26
Takeda (TAK) has announced that the FDA has accepted its marketing application for the label expansion of its inflammatory bowel disease therapy, Entyvio, for pediatric use in the U.S. The FDA has set a target action date for the approval in Q1 2027. This acceptance marks a step towards making the treatment more widely available for children with inflammatory bowel disease.
2026-06-10 10:09:16
Takeda Pharmaceutical Company Limited will issue 16,989,076 ordinary shares on July 8, 2026, for its Long Term Incentive Plan (LTIP) to 10,557 employees outside Japan. The grant, valued at 85,794,833,800 yen (5,050 yen per share), includes both new and treasury shares, to be settled primarily in American depositary shares or cash. This move aims to align employee interests with shareholders, attract and retain talent, and balance risk and reward through performance-based vesting conditions.
